Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.

ABSTRACT: COVID-19 vaccine design and vaccination rollout need to take into account a detailed understanding of antibody durability and cross-neutralizing potential against SARS-CoV-2 and emerging variants of concern (VOCs). Analyses of convalescent sera provide unique insights into antibody longevity and cross-neutralizing activity induced by variant spike proteins, which are putative vaccine candidates. Using sera from 38 individuals infected in wave 1, we show that cross-neutralizing activity can be detected up to 305 days pos onset of symptoms, although sera were less potent against B.1.1.7 (Alpha) and B1.351 (Beta). Over time, despite a reduction in overall neutralization activity, differences in sera neutralization potency against SARS-CoV-2 and the Alpha and Beta variants decreased, which sug

SUBMITTER: Dupont L 

PROVIDER: S-EPMC8556155 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature